Last reviewed · How we verify
Trisoralen (TRIOXSALEN)
Trisoralen (Trioxsalen) is a small molecule psoralen drug that targets the adenosine receptor A2a. Originally developed and currently owned, it was first approved by the FDA in 1964 for the treatment of photosensitivity, skin pigmentation enhancement, and vitiligo. As an off-patent medication with no active Orange Book patents, it is available from generic manufacturers. Key safety considerations include the risk of photosensitivity reactions and potential interactions with other medications. Trisoralen is a well-established treatment option for its approved indications.
At a glance
| Generic name | TRIOXSALEN |
|---|---|
| Drug class | Psoralen |
| Target | Adenosine receptor A2a |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
| First approval | 1964 |
Approved indications
- Photosensitivity
- Skin Pigmentation Enhancement
- Vitiligo
Common side effects
Key clinical trials
- Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery (PHASE1)
- Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma (PHASE2)
- Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease (PHASE1)
- Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma (PHASE2)
- Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer (PHASE1,PHASE2)
- Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer (PHASE1)
- Afamelanotide as Adjunctive Therapy in Patients Undergoing Photodynamic Therapy (PDT) Utilising Porfimer Sodium (PHASE2)
- Novel Light Delivery Methods for Lung Cancer Photodynamic Therapy - A Pilot Study (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trisoralen CI brief — competitive landscape report
- Trisoralen updates RSS · CI watch RSS